What is the appropriate treatment for a 44‑year‑old female with severe osteoporosis secondary to an undiagnosed empty sella and an axis (C2) fracture?

Treatment for C2 Fracture with Severe Osteoporosis Secondary to Empty Sella

For this 44-year-old woman with severe osteoporosis from empty sella syndrome and a C2 fracture, initiate immediate teriparatide (anabolic therapy) followed by transition to bisphosphonates, while simultaneously addressing the underlying endocrine deficiencies and providing acute fracture stabilization.

Acute C2 Fracture Management

The C2 fracture requires immediate orthopedic/neurosurgical consultation for stabilization decisions. Most C2 fractures in severe osteoporosis require:

• Rigid cervical immobilization (halo vest or rigid collar depending on fracture pattern)
• Surgical fixation may be necessary depending on fracture stability and displacement
• The severe osteoporosis complicates surgical fixation and increases non-union risk 1

Address the Underlying Empty Sella Syndrome

Empty sella syndrome causes multiple pituitary hormone deficiencies that directly caused this severe osteoporosis 2. Immediate endocrine evaluation is critical:

• Check: TSH, free T4, free T3, morning cortisol, ACTH, testosterone (if applicable), prolactin, IGF-1, LH, FSH
• The case report demonstrates empty sella can cause low testosterone, low thyroid hormones, and elevated prolactin—all contributing to severe osteoporosis 2
• Replace deficient hormones immediately: thyroid hormone, cortisol (if deficient), and sex hormones as this is essential for fracture healing and preventing further bone loss 3

Pharmacologic Osteoporosis Treatment

Start with teriparatide (anabolic agent) as first-line therapy given the severity of disease 1. This patient meets criteria for "very severe osteoporosis" with:

• Age 44 (premenopausal age with severe disease)
• Vertebral (C2) fracture
• Secondary osteoporosis from endocrine disorder

Rationale for Anabolic-First Approach:

Teriparatide is specifically recommended for patients with very severe osteoporosis 1. The guidelines explicitly state: "For patients with very severe osteoporosis, the use of anabolic agents such as teriparatide is an option" 1.

• Teriparatide demonstrates real increases in both trabecular and cortical bone volume 4
• More effective than bisphosphonates alone in severe disease 5
• Superior to risedronate in preventing vertebral and clinical fractures in patients with existing vertebral fractures 5
• The proportion of inadequate-responders to bisphosphonates increases with disease severity 4

Treatment Sequence:

1. Teriparatide 20 mcg subcutaneous daily for 18-24 months 4, 5
2. Transition to bisphosphonate (alendronate or zoledronic acid) after completing teriparatide to maintain bone gains 4, 5
   • This sequential approach is critical: introducing antiresorptive after teriparatide prevents reabsorption of new bone and further increases BMD 4
   • Risk of rebound vertebral fractures if antiresorptive not started after anabolic therapy 6

Alternative if Teriparatide Unavailable:

If teriparatide cannot be obtained, the 2023 ACP guideline suggests romosozumab for females at very high fracture risk 6, though this is a conditional recommendation with low-certainty evidence.

If anabolic therapy is absolutely not available: Start oral bisphosphonate (alendronate 70 mg weekly or risedronate 35 mg weekly) as these are first-choice agents 7. However, recognize this is suboptimal for severe disease 4, 8.

Supportive Therapy (Essential, Not Optional)

• Calcium 1000-1200 mg/day (dietary plus supplementation if needed) 1, 9
• Vitamin D 800 IU/day targeting serum 25-OH vitamin D ≥30 ng/mL 1, 3
• These are mandatory when using anti-osteoporosis drugs 1

Critical Pitfalls to Avoid

1. Do not use bisphosphonates alone as first-line in this severe case—they are suboptimal for very severe osteoporosis and this patient needs bone building, not just preservation 4, 8

2. Do not stop teriparatide without transitioning to bisphosphonate—this causes rapid bone loss and rebound fracture risk 6, 4

3. Do not treat osteoporosis without correcting the underlying endocrine deficiencies—hormone replacement is essential for fracture healing and preventing further bone loss 3, 2

4. Avoid high-dose pulse vitamin D—associated with increased fall risk 1

5. Do not use raloxifene, estrogen therapy, or calcitonin—these are explicitly not recommended 7

Monitoring and Duration

• Treat with teriparatide for 18-24 months, then transition to bisphosphonate for 3-5 years minimum 1, 4
• Given persistent high risk from secondary osteoporosis, longer treatment duration likely needed 1
• Do not monitor BMD during initial 5-year treatment period—fracture reduction occurs even without BMD increase 7
• Monitor adherence systematically as this is critical for efficacy 1

Multidisciplinary Coordination Required

This case demands collaboration between:

• Orthopedic surgery/neurosurgery (C2 fracture stabilization)
• Endocrinology (hormone replacement for empty sella)
• Primary care or metabolic bone specialist (osteoporosis management)

The critical point is ensuring all aspects receive optimal care simultaneously 1.